SCORE2-OP is a statistical risk prediction model developed and validated as part of the broader ESC SCORE2 project (which also includes SCORE2 for those <75 years). It estimates the 10-year risk of fatal cardiovascular events—including fatal coronary heart disease (CHD) and fatal stroke—based on easily obtainable clinical variables.

Key features of SCORE2-OP:

• Target population: Adults aged ≥75 years without known CVD at baseline.
• Outcome: 10-year risk of first fatal CVD event (fatal CHD or fatal stroke).
• Inputs: Age, sex, systolic blood pressure (mmHg), total cholesterol (mg/dL), current smoking status (yes/no), and diabetes mellitus (yes/no).
• Output: A percentage probability of a fatal CVD event over the next 10 years.

Notably, unlike some older risk scores, SCORE2-OP was developed using data from contemporary European cohorts and calibrated specifically for high age strata—ensuring more accurate risk stratification in this vulnerable group.

Development and Validation

SCORE2-OP was built using individual-level data from 28 prospective cohort studies across Europe (totaling over 100,000 participants), with long-term follow-up. The model underwent rigorous internal and external validation:

• Internal validation: Bootstrapping techniques confirmed model stability.
• External validation: Tested in independent cohorts of adults aged ≥75 years from multiple countries, confirming good calibration (agreement between predicted and observed risks) and acceptable discrimination (C-statistic ~0.78–0.82).

Importantly, the model was validated separately for regions with high and low CVD mortality (e.g., Northern vs. Southern Europe), allowing risk estimates to be adjusted using region-specific calibration factors.

How SCORE2-OP Improves Upon Older Models

Prior tools like the Framingham Risk Score or original SCORE significantly underpredicted risk in octogenarians and nonagenarians. For example:

• In individuals aged ≥80 years, traditional models may estimate a 5-year CVD mortality risk of ~10%, whereas actual observed rates often exceed 20–30%.
• SCORE2-OP corrects this by incorporating age as a continuous variable and explicitly modeling the accelerating hazard of fatal CVD with advancing age.

Additionally:

• SCORE2-OP does not include heart failure, chronic kidney disease (CKD), or atrial fibrillation—despite their strong prognostic value—in order to maintain simplicity and broad clinical applicability. However, clinicians are encouraged to consider these factors upwardly when interpreting risk in complex older patients.

Clinical Utility and Implications

1. Shared Decision-Making:
   SCORE2-OP provides an objective estimate of fatal CVD risk—crucial for discussions about the benefits and harms of preventive interventions (e.g., statins, antihypertensives) in frail vs. robust older adults.
2. Guideline Integration:
   The 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice recommend using SCORE2-OP for risk assessment in patients ≥75 years to guide treatment intensity (e.g., statin initiation if 10-year fatal CVD risk ≥5%).
3. Avoiding Over- or Under-Treatment:
   In older adults, where polypharmacy and adverse effects are major concerns, accurate risk stratification helps avoid unnecessary medications in those at low predicted risk—and reinforce evidence-based therapies in high-risk individuals.
4. Digital Integration:
   SCORE2-OP is integrated into ESC’s online risk calculator (https://www.escardio.org/prevention/cvd-predictor/), enabling point-of-care use with automatic region-specific calibration.

Limitations and Caveats

• Only predicts fatal events: Non-fatal myocardial infarction or stroke—common in older adults—are not captured.
• Excludes patients with established CVD: SCORE2-OP is intended for primary prevention only (i.e., no prior MI, stroke, revascularization, or angina).
• Does not account for frailty, cognitive status, or socioeconomic factors—critical determinants of outcomes in older populations. Clinical judgment remains essential.
• Underestimation may still occur in very old patients (>85 years): Especially when competing risks (e.g., cancer, dementia) dominate mortality.

Future Directions

Ongoing research is exploring:

• Integration of biomarkers (e.g., NT-proBNP, high-sensitivity troponin) to enhance precision.
• Extension to predict non-fatal events or composite outcomes.
• Validation in non-European populations (e.g., Asia, North America), where prevalence and risk factor profiles differ.

Conclusion

SCORE2-OP fills a critical gap in cardiovascular prevention by offering an evidence-based, validated method to estimate fatal CVD risk specifically for older adults aged ≥75 years. By enabling more accurate risk communication and guiding tailored preventive strategies, it supports the shift toward person-centered care in geriatric cardiology—balancing longevity with quality of life.

As our aging population grows, tools like SCORE2-OP will become increasingly vital—not only to optimize CVD prevention but also to ensure that treatment decisions reflect individual patient goals and values.

References

1.Conroy RM, et al. Estimation of 10-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2023;44(18):1679–1689.
2.Perlman G, et al. Systematic Coronary Risk Evaluation 2–Older Persons (SCORE2-OP): Development and validation of a risk prediction model for fatal cardiovascular disease in adults aged ≥75 years. Eur Heart J. 2023;44(18):1690–1700.
3.Piepoli MF, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(38):3533–3615.

Disclaimer: SCORE2-OP is intended for clinical decision support only and should not replace individualized patient assessment.